Cyclosporin A and Drug Interaction

  • R. Menta
  • S. David
  • V. Cambi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 252)


Studies of drug interactions during Cyclosporin A (CyA) therapy are based mostly on spontaneous reports. Between 1985 and 1987 35 significant clinical manifestations arising from pharmacological interaction were published by three major medical journals. This work is a summary of clinical complications after combined use of CyA and several other drugs.


Acute Rejection Area Under Curve Renal Transplant Patient Renal Denervation Methylprednisolone Pulse Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. (1).
    F. Aramburu, B. Begaud, J.C. Pere, S. Marcel and H. Albin, Role of Medicine Journals in Adverse Drugs Reaction Alerts, Lancet ii:550 (1985)CrossRefGoogle Scholar
  2. (2).
    J.C. Roujean, J.C. Guillaume, J. Revuz and R. Touraine: Reporting Adverse Drug Reaction, Lancet ii:1244 (1985)CrossRefGoogle Scholar
  3. (3).
    N. Moore, M. Biour, G. Paux, E. Loupi, B. Begaud, F. Boismare and R.J. Roxer, Adverse Drug Reaction Monitoring: Doing the French Way, Lancet ii: 1056 (1985)Google Scholar
  4. (4).
    P.H. Whiting, M.D. Burke and A.W. Thomson, Drug Interaction with Cyclosporin. Implication from Animal Studies, Trans. Proc. XVIII, 6:56 (1986)Google Scholar
  5. (5).
    W. Niederbenger, M. Lemarie, G. Maurer, K. Nussbaumer and O. Wagner, Distribution and Binding of Cyclosporin in Blood and Tissue, Trans. Proc. XV:2419 (1983)Google Scholar
  6. (6).
    M.D. Burke and P.H. Whiting, The Role of Drug Metabolism in Cyclosporin A Nephrotoxicity, CI. Nephrol. 25 (SI):S111-S117 (1986)Google Scholar
  7. (7).
    R.J. Caterson, G.G. Dugging, L. Critchley, C. Baxter, J.S. Horvat, B.M. Hall and D.J. Tiller, Renal Tubular Transort of Cyclosporin A and Associated Changes in Renal Function, CI. Nephrol. 25(S1):S30 (1986)Google Scholar
  8. (8).
    P.H. Whiting, A.W. Thompson and J.G. Simpson, Cyclosporin Toxicity, Metabolism and Drug Interaction. Implications from Animal Studies, Trans. Proc. XVII:134 (1985)Google Scholar
  9. (9).
    R.A. Coward, A.T. Raftery and C.B. Brown, Cyclosporin and Antitubercolous Therapy, Lancet i:1342 (1985)CrossRefGoogle Scholar
  10. (10).
    W.A. Jurewicz, B.K. Gunson, T. Ismail, L. Angrisani and P. McMaster, Cyclosporin and Antitubercolous Therapy, Lancet i:1343 (1985)Google Scholar
  11. (11).
    D.L. Modry, E.B. Stinson, P.E. Oyer, S.W. Jameson, J.C. Baldwin and N.E. Shuhway, Acute Rejection and Massive Cyclosporin Requirements in Heart Transplant Recipients Treated with Rifampicin, Transplantation 39:313 (1985)PubMedCrossRefGoogle Scholar
  12. (12).
    P.H. Whiting, Generalized epileptic Fits in Renal Transplant recipients Given Cyclosporin A, Br. Med. J. 1:162 (1985)Google Scholar
  13. (13).
    P. Lele, P. Peterson, S. Tang, B. Jarrell and J.F. Burke, Cyclosporin and Tegretal – Another Drug Interaction, Kidney Int. 27:344 (1985)Google Scholar
  14. (14).
    D.K. Jones; M. Hakim, J. Wallwork and T.W. Higenbottam, Serious Interaction between Cyclosporin A and Sulphamidine, Br. Med. J. 292:728 (1986)CrossRefGoogle Scholar
  15. (15).
    S.A. Veremis, M.S. Maddux, R. Pollak and M.F. Mozes, Subtherapeutic Cyclosporin Concentrations During Nafcillin Therapy, Transplantation 1:913 (1987)Google Scholar
  16. (16).
    Cyclosporin a New Immunosuppressive Drug, Medical Letter 25:77(1985)Google Scholar
  17. (17).
    R. Ptachinski, B. J. Carpenter, G.J. Burckart, R. Venkataramanan and J.T. Rosenthal, Effect of Erythromycin on Cyclosporin Levels, N. Engl. J. Med. 2:1416 (1985)Google Scholar
  18. (18).
    D.E. Kohan, Possible Interaction between Cyclosporin and Erythromycin, N. Engl. J. Med. 1:448 (1986)Google Scholar
  19. (19).
    P. Vereet Straeten, P. Thiry, P. Kinnaert and C. Toussaint, Influence of Erythromycin on Cyclosporin Pharmacokinetics, Transplantation S (July) 44:155 (1987)Google Scholar
  20. (20).
    R. Martell, D. Heinrichs, C.R. Stiller, M. Jenner, P.A. Keown and J. Dupre, The Effects of Erythromycin in Patients treated with Cyclosporin, Ann. Int. Med. 104:660 (1986)PubMedGoogle Scholar
  21. (21).
    H. Dieperink and J. Moller, Ketoconazole and Cyclosporin, Lancet 2:1217 (1987)Google Scholar
  22. (22).
    J.T.C. Kwan, P.D. Foxall, D.G.C. Davidson, M.R. Bending and A.J. Eisinger, Interaction of Cyclosporin and Itraconazole, Lancet 2:282 (1987)PubMedCrossRefGoogle Scholar
  23. (23).
    M.D. Burke and P.H. Whiting, The Role of Drug Metabolism in Cyclosporin A Nephrotoxicity, CI. Nephrol. 25:111 (1986)Google Scholar
  24. (24).
    M.A. Boogaerts, P. Zachee and R.L. Verwilghen, Cyclosporin, Methilprednisolone and Convulsions, Lancet 2:1216 (1982)PubMedCrossRefGoogle Scholar
  25. (25).
    E. Langhoff, S. Madsen, H. Flachs, K. Olgaard, J. Ladefoged and E. Hvidberg, Inhibition of Prednisolone Metabolism by Cyclosporin in kidney Transplanted Patients, Transplantation 39:106 (1985)CrossRefGoogle Scholar
  26. (26).
    L. Oest, Effects of Cyclosporin on Prednisolone Metabolism, Lancet 2:451 (1984)CrossRefGoogle Scholar
  27. (27).
    G. Klintmalm and J. Save, High Dose Methylprednisolone Increases Plasma Cyclosporin Levels in Renal Transplant Recipients, Lancet 1:731 (1984)PubMedCrossRefGoogle Scholar
  28. (28).
    B. Broch Moller and B. Ekelund, Toxicity of Cyclosporin During Treatment with Androgens, N. Engl. J. Med. 2:1416 (1985)Google Scholar
  29. (29).
    G. Deray, P. Hoang, P. Cacoub, V. Assogba, P. Grippon and A. Baumelan, Oral Contraceptive Interaction with Cyclosporin, Lancet 1:158 (1987)PubMedCrossRefGoogle Scholar
  30. (30).
    J.M. Pochet and Y. Pirson, Cyclosporin-Diltazem Interaction, Lancet 1:979 (1986)PubMedCrossRefGoogle Scholar
  31. (31).
    K. Wagner and H.H. Neumayer, Prevention of Delayed Graft Function in Cadaver Kidney Transplants by Diltiazem, Lancet 2:1355 (1985)PubMedCrossRefGoogle Scholar
  32. (32).
    B. Bourbigot, J. Guiserix, J. Airiau, L. Bressolette, J.F. Morin and J. Cledes, Lancet 1:1447 (1986)PubMedCrossRefGoogle Scholar
  33. (33).
    A. Lindholm and S. Henricsson, Verapamil Inhibits Cyclosporin Metabolism, Lancet 1:1262 (1987)PubMedCrossRefGoogle Scholar
  34. (34).
    J. Zazgornick, J. Schneider. G. Gremmel, P. Balcke, H. Kopsa, K. Derfler and E. Minar, Ranitidine Does not Influence the Blood Cyclosporin Levels in Renal Transplant Patients (RTP) Kidney Int. 6:401 (1986)Google Scholar
  35. (35).
    M. Jarowenko, C.T. Van Buren, W.G. Kramer, M.I. Lorber, S. Flechner and B. Kaham, Ranitidine, Cimetidine and the Cyclosporin-Treated Recipient, Transplantation 42:311 (1986)PubMedCrossRefGoogle Scholar
  36. (36).
    C. Hiesse, M. Cantarovich, C. Santelli, P. Francais, B. Charpentier, D. Fries and C. Buffet, Ranitidine Hepatotoxicity in Renal Transplant Patient, Lancet 1:1280 (1985)PubMedCrossRefGoogle Scholar
  37. (37).
    M.A. Souza Lima, Hepatitis Associated with Ranitidine, Ann. Int. Med. 101:207 (1984)Google Scholar
  38. (38).
    M. Black, W.E. Scott and R. Kanter, Possible Ranitidine Nephrotoxicity, Ann. Int. Med. 101:208 (1984)PubMedGoogle Scholar
  39. (39).
    R. Menta, E. Rossi, A. Guariglia, S. David and V. Cambi, Reversible Acute Cyclosporin Nephrotoxicity Induced by Colchicine Administration, Nephrol. Dial. Transplant. 2:380 (1987)PubMedGoogle Scholar
  40. (40).
    P.C. Johonson, K. Kumor, M.S. Welsh, J. Woo and B. Kahan, Effects of Coadministration of Cyclosporin and Acyclovir on Renal Function of Renal Allograft Recipients, Transplantation 44:329 (1987)CrossRefGoogle Scholar
  41. (41).
    D. Brigden, A.E. Rosling and N.C. Woods, Renal Function after Acyclovir Intravenous Injection, Am. J. Med. 73:182 (1982)PubMedCrossRefGoogle Scholar
  42. (42).
    M.S. Kennedy, H.J. Deeg, M. Siegel, J.J. Crowley, R. Storb and E.D. Thomas, Acute Renal Toxicity with Combined Use of Amphotericin B and Cyclosporin after Marrow Transplantation, Transplantation 35:211 (1983)PubMedCrossRefGoogle Scholar
  43. (43).
    A. Termeer, A.J. Hoitsma and R.A.P. Koene, Severe Nephrotoxicity Caused by the Combined Use of Gentamicin and Cyclosporin in Renal Allograft Recipients Transplantation 42:221 (1986)Google Scholar
  44. (44).
    P.H. Whiting, J.D. Simpson, R.J.C. Davidson and A.W. Thomson, The Toxic Effects of Combined Administration of Cyclosporin A and Gentamicin, Br. J. Exp. Pathol. 63:554 (1982)PubMedGoogle Scholar
  45. (45).
    J.R. Mitchell, W.Z. Potter, J.A. Minson and D.J. Jollow, Hepatic Necrosis Caused by Frusemide, Nature 251:508 (1974)PubMedCrossRefGoogle Scholar
  46. (46).
    P.H. Whiting, C. Cunningham, A.W. Thomson and J.G. Simpson, Enhancement of High Dose Cyclosporin A Toxicity By Frusemide, Bioch. Pharm. 33:1074 (1984)CrossRefGoogle Scholar
  47. (47).
    S.S. Thorgeirsson, H.A. Sasame, J.R. Mitchell, D.J. Jallow and W.Z. Potter, Biochemical Changes after Hepatic Injury from Toxic Doses of Acetaminophen or Furosemide, Pharmacology 14:205 (1976)PubMedCrossRefGoogle Scholar
  48. (48).
    F.P. Brunner, M. Hermle, M.J. Mihatsch and G. Thiel, Mannitol Potentiates Cyclosporin Nephrotoxicity, CI. Nephrol. 25:130 (1986)Google Scholar
  49. (49).
    J. Thompson, D.H.K. Chalmers, A.G.W. Hunnisett, R.F.M. Wood and P.J. Morris, Nephrotoxicity of Trimethoprim and Cotrimoxazole in Renal Allograft Recipients Treated with Cyclosporin, Transplantation 36:204 (1982)Google Scholar
  50. (50).
    C. Cunningham, P.H. Whiting, M.D. Burke, D.N. Wheatley and J.G. Simpson, Increasing the Hepatic Metabolism of Cyclosporin Abolishes Nephrotoxicity, Trans. Proc. XV:2713 (1983)Google Scholar
  51. (51).
    J.F. Gerkens and A.J. Smith, Effect of Captopril and Theophylline Treatment on Cyclosporin-Induced Nephrotoxicity in Rats, Transplantation 40:214 (1985)CrossRefGoogle Scholar
  52. (52).
    T.L. Kho, K.M. Leunissen, G.A.K. Heidendhal, P. Lijnen, A. Amery and J.P. Van Hoff, Nephrotoxic Effect of Cyclosporin A can be Reversed by Dopamine Nephrol. Dial. Transplant. 1:140 (1986)Google Scholar
  53. (53).
    T.L. Kho, R. Kengen, K.M.L. Leunissen, J. Teule and J.P. Van Hooff, Hydergine and Reversibility of Cyclosporin Nephrotoxicity, Lancet 2:394 (1986)PubMedCrossRefGoogle Scholar
  54. (54).
    R.B. Nussènblatt, H.A. Austin, A.G. Palestine and H.G. Preuss, Hydergine and Cyclosporin Nephrotoxicity, Lancet 1:1220 (1986)PubMedCrossRefGoogle Scholar
  55. Makowka, W. Lopatin, T. Gilas, J. Falk, W.J. Phillips and R. Falk, Prevention of Cyclosporin Nephrotoxicity by Synthetic ProstaglandinsGoogle Scholar
  56. (56).
    B. Ryffel, P. Donatsch, P. Hiestafid and M.J. Mihatsch, PGE2 Reduces Nephrotoxicity and Immunosuppression of Cyclosporin in Rats, CI. Nephrol. 25:95 (1986)Google Scholar
  57. (57).
    B.M. Murray and M.S. Palier, Beneficial Effects of Renal Denervation and Prazosin on GFR and Renal Blood Flow after Cyclosporin in Rats CI. Nephrol. 25:37 (1986)Google Scholar
  58. (58).
    R. Sibley, J. Rynasiewicz, R.M. Ferguson, D. Fryd, D.E.R. Sutherland, R.L. Simmons and J.S. Najarian, Morphology of Cyclosporin and Prednisone, Surgery 94:225 (1983)PubMedGoogle Scholar
  59. (59).
    B.D. Meyers, J. Ross, L. Newton, J. Luetscher and M. Perlroth, Cyclosporin-Associated Cronic Nephropathy, N. Engl. J. Medv 311:699 (1984)CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1989

Authors and Affiliations

  • R. Menta
    • 1
  • S. David
    • 1
  • V. Cambi
    • 1
  1. 1.Cattedra di NefrologiaUniversità degli Studi di ParmaParmaItaly

Personalised recommendations